Skip to content
OpenCapital
Get started
Castle Biosciences logo

Castle Biosciences (CSTL) Q1 2026 Earnings

CSTL·Reported May 6, 2026·After market close

Castle Biosciences reported Q1 2026 revenue of $84.2M (-4.3% YoY), beat analyst consensus of $79.2M by $5.0M. Diluted EPS came in at $-0.49 (-145.0% YoY).

Revenue
$84.2Mbeat by $5.0M
Consensus: $79.2M
Diluted EPS
$-0.49met estimate
Consensus: $-0.49
SEC

SEC Filings

Earnings release8-K · 0001628280-26-031255
Quarterly report10-Q · 0001628280-26-031263

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Castle Biosciences's Q1 2026 earnings report.

Castle Biosciences (CSTL) reported Q1 2026 earnings on May 6, 2026 after market close.

Castle Biosciences reported revenue of $84.2M and diluted EPS of $-0.49 for Q1 2026.

Revenue beat the consensus estimate of $79.2M by $5.0M. EPS beat the consensus estimate of $-0.49 by $0.00.

Compared to the same quarter a year prior, revenue declined 4.3% from $88.0M a year earlier and diluted EPS declined 145.0% from $-0.20.

You can read the 8-K earnings release (0001628280-26-031255) and the 10-Q periodic report (0001628280-26-031263) directly on SEC EDGAR. The filing index links above go to sec.gov.